Maria Sundvall
MD PhD; Specialist Physician in Clinical Oncology
mahesu@utu.fi Kiinamyllynkatu 10 Turku |
clinical oncology; breast and prostate cancer; targeted cancer therapeutics; cancer biology; cell signaling; posttranslational modifications; dna repair pathways
Maria Sundvall received her MD degree from the University of Turku in 2003, and defended her PhD thesis at the Department of Medical Biochemistry and Genetics, University of Turku, in 2007. From 2011 she worked nearly 4 years as a postdoctoral fellow in the laboratory of Prof. Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. After returning to Finland in 2015 she established her own research group at the University of Turku. Dr. Sundvall received a specialist physician degree in clinical oncology in 2018. Since 2018 Dr. Sundvall has worked as a part-time clinical lecturer at the Institute of Biomedicine, a part-time Academy of Finland clinical researcher and a part-time specialist physician in clinical oncology at Turku University Hospital.
Dr. Sundvall has 20 years of experience in studying molecular mechanisms of cancer. Currently she is a principal investigator at University of Turku, and her group is focusing on investigating the role fo DNA repair pathways in prostate cancer. Links:
https://www.utu.fi/en/university/faculty-of-medicine/institute-of-biomedicine/research/cancer-research
Dr. Sundvall has several years of experience in teaching medical students as a clinical lecturer and a university teacher in the fields of medical biochemistry, molecular medicine and cancer during the last 15 years.
- High comorbidity and tumor proliferation predict survival of localized breast cancer patients after curative surgery: A retrospective analysis of real-world data in Finland (2025)
- Surgical Oncology
- Phage Biosensor for the Classification of Metastatic Urological Cancers from Urine (2024)
- LifeFrontiers in Oncology
- Syövän kohdennettujen lääkehoitojen tulevaisuus (2024)
- Duodecim
- TIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicity (2024)
- Genes and Immunity
- xCT as a Predictor for Survival in a Population‐Based Cohort of Head and Neck Squamous Cell Carcinoma (2024)
- Cancer MedicineDuodecim
- Effect of caldesmon mutations in the development of zebrafish embryos (2023)
- Biochemical and Biophysical Research Communications
- Glucocorticoid receptor-induced non-muscle caldesmon regulates metastasis in castration-resistant prostate cancer (2023)
- Oncogenesis
- Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study (2023)
- Cancer Medicine
- TSPO is a potential independent prognostic factor associated with cellular respiration and p16 in head and neck squamous cell carcinoma (2023)
- Ex vivo -mallit ja nestebiopsia yksilöllistetyssä syövänhoidossa (2021)
- Duodecim
- Geeniohjatun syövän hoidon työryhmä hoitopäätösten apuna : Läntisen syöpäkeskuksen kokemus (2021)
- More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond (2021)
- Cancers
- Therapeutic Potential of Targeting the SUMO Pathway in Cancer (2021)
- Cancers
- Role of Ubiquitin and SUMO in Intracellular TraffickingERBB4 Promoter Polymorphism Is Associated with Poor Distant Disease-Free Survival in High-Risk Early Breast Cancer (2020)
- Current Issues in Molecular BiologyPLoS ONE
- Uusia työkaluja paikallisesti edenneen ja etäpesäkkeisen eturauhassyövän lääkehoitoon (2020)
- Duodecim
- PARP Inhibitors in Prostate Cancer-the Preclinical Rationale and Current Clinical Development (2019)
- Genes
- Role of Ubiquitin and SUMO in Intracellular Trafficking (2019) SUMOylation and Ubiquitination: Current and Emerging Concepts Maria Sundvall
- Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin (2018)
- Scientific Reports
- SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase (2017)
- Journal of Biological Chemistry
- (2014)